Tuesday, March 24, 2026

Phase 2 Data Support OCU410 in GA

After positive 12-month results from the ArMaDa trial, Ocugen plans a registrational phase 3 study of its investigational gene therapy.

Monday, March 23, 2026

MLSDT Shows Promise as Functional Vision Measure in RP

A recent study finds the Multi-Luminance Shape Discrimination Test correlates with visual acuity, visual fields, and patient-reported outcomes.

Wednesday, March 18, 2026

Kalaris Reports Phase 1a Results for TH103

Early data in treatment-naïve nAMD show visual gains and favorable pharmacokinetics.

Tuesday, March 10, 2026

VIS-101 Shows Activity in nAMD Study

Data from a phase 2a study in China suggest visual acuity gains and potential treatment durability.

Tuesday, March 3, 2026

Axpaxli Data Presented at Macula Society Meeting

During a symposium, investigators presented findings from the phase 3 SOL-1 trial highlighting the intravitreal insert’s durability and improved visual outcomes in patients with nAMD.

Monday, March 2, 2026

EyePoint Begins Phase 3 Trials of Duravyu for DME

COMO and CAPRI will evaluate the intravitreal vorolanib insert vs the standard of care in treatment-naïve and previously treated patients with diabetic macular edema.

Monday, March 2, 2026

First Patient Treated in Trial for BEST1-Related Disease

Early functional and anatomical gains observed at 3 months in the first adult patient treated with the subretinal gene therapy.

Thursday, February 19, 2026

Prevent Blindness Declares Third Annual ROP Awareness Week

As part of its ongoing ROP Education and Support Initiative, Prevent Blindness has declared the third annual Retinopathy of Prematurity (ROP) Awareness Week, Feb. 23 to March 1.

Wednesday, February 18, 2026

Ametek Acquires LKC Technologies

The deal adds ERG-focused retinal diagnostics to Ametek's portfolio.

Wednesday, February 11, 2026

NIH Builds Digital Model of RPE Cells

The AI-driven 3D model maps polarity changes relevant to AMD progression, which could guide future therapeutic approaches.

Tuesday, February 10, 2026

4DMT Completes Enrollment in Gene Therapy Trial for Wet AMD

The phase 3 4FRONT-1 study compares 4D-150, an investigational gene therapy, against aflibercept 2 mg in treatment-naïve patients.

Friday, February 6, 2026

ZipBio Licenses GA Program to MeiraGTx

The agreement grants MeiraGTx exclusive rights to ZipBio’s complement-targeting therapies for geographic atrophy.

Tuesday, February 3, 2026

DR Screening Integrated into Epic EMR

The Aeye-DS device uses AI to allow non-ophthalmic providers to capture retinal images and screen for diabetic retinopathy.

Tuesday, February 3, 2026

Zeiss Gains Chinese Approval for Surgical Microscopes

Artevo 750 and 850 integrate digital and optical visualization for ophthalmic surgery.

Wednesday, January 28, 2026

Opus Genetics Launches MERTK Gene Therapy Trial

The Abu Dhabi–based study will evaluate an investigational AAV therapy for MERTK-related retinitis pigmentosa.

Monday, January 26, 2026

FDA Clears Novaliq Uveitis Program

NOV05, a topical tacrolimus ophthalmic solution, is set to enter a phase 2 trial in patients with noninfectious anterior uveitis.

Monday, January 26, 2026

FDA Grants Orphan Drug Status to OpCT-001

The investigational cell therapy from Bayer AG/BlueRock Therapeutics is being studied for inherited photoreceptor diseases, including retinitis pigmentosa.

Thursday, January 22, 2026

PulseSight Completes Enrollment in Gene Therapy Trial

The French company’s PST-611, which is being evaluated in a phase 1 trial, targets iron dysregulation in dry AMD and geographic atrophy.

Tuesday, January 20, 2026

MCO-010 Receives Accelerated Pathway in Japan

Sakigake designation supports expedited review; FDA, EMA, and Japan conditionally approve the brand name Mogenry for Nanoscope’s optogenetic therapy.

Tuesday, January 20, 2026

OCU410 Shows Early Efficacy in GA Trial

Interim ArMaDa data show a reduction in lesion growth with no serious safety signals reported for Ocugen's investigational gene therapy.

Friday, January 16, 2026

AAVantgarde Completes Enrollment in LUCE-1

The phase 1/2 trial is evaluating a dual-AAV gene therapy for Usher syndrome type 1B.

Tuesday, January 13, 2026

Topcon Partners With RemoniHealth on Remote Monitoring

The companies will collaborate on home monitoring and connected care for chronic retinal disease.

Thursday, January 8, 2026

Ollin Biosciences Reports Positive OLN324 Results

The next-generation VEGF/Ang2 bispecific antibody demonstrates rapid retinal drying and vision gains in patients with diabetic macular edema.

Thursday, January 8, 2026

Gene Therapy for GA Receives FDA Fast-Track Designation

Complement Therapeutics’s CTx001, an investigational gene therapy that targets complement pathways in geographic atrophy, will be evaluated in a phase 1/2 trial in 2026.

Wednesday, January 7, 2026

Nanoscope Receives Patent for Optogenetic Platform

The patent extends US intellectual property protection for Nanoscope’s multicharacteristic opsin (MCO) platform through at least 2039.

Tuesday, January 6, 2026

Ikarovec Secures Capsid Option for AMD Program

The partnership with VectorBuilder aims to advance IKAR-003, an intravitreal gene therapy designed to slow AMD progression.

Tuesday, January 6, 2026

Privosegtor Receives Breakthrough Drug Designation

In a phase 2 trial, the drug showed functional and structural signals in optic neuritis.

Friday, January 2, 2026

FDA Approves Ranibizumab Biosimilar

Ranibizumab-leyk (Nufymco) is approved for for wet AMD, DME, DR, RVO-related macular edema, and myopic CNV.

Friday, January 2, 2026

FDA Seeks Additional Efficacy Evidence for ONS-5010

The agency says Outlook Therapeutics must provide additional evidence confirming the efficacy of its intravitreal bevacizumab formulation for wet AMD.

Friday, January 2, 2026

Visual Evoked Potentials Studied to Measure Outcomes in Children Treated With Gene Therapy for RPE65 IRD

Results underscore the potential of alternate objective measures in the pediatric population.